BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis who received 12 weeks of combination induction therapy with guselkumab and golimumab.

Merck, known as MSD outside of the United States and Canada, announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension .

First Wave BioPharma, Inc., announced today that research demonstrating key advantages of its improved adrulipase drug delivery formulation will be the subject of a poster presentation at AAPS 2022 PharmSci 360 on October 19 at 9:30 a.m.

Orchard Therapeutics today announced multiple presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh.

Immunic, Inc. today announced it has entered into a securities purchase agreement (the " Purchase Agreement ") with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock.

Nevro Corp. today announced that on October 1, 2022 , UnitedHealthcare (“United”) released an update to its medical coverage policy ( number 2022T0567V ) and added language to indicate spinal cord stimulation (SCS) devices are not covered for treating chronic intractable back pain without prior spine surgery (NSBP).

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program.

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update for the IMA203 monotherapy covering the completed Phase 1a dose escalation part of the trial and initial data from the first 5 patients in the ongoing Phase 1b dose expansion cohort A (monotherapy).

Henry Schein, Inc. (Nasdaq: HSIC) announced today that it has been named to FORTUNE® magazine’s “Change the World” list, an annual recognition of select companies that, through their work and initiatives, create positive social impact as part of their core business strategy.

CompIQ Solutions, a technology-focused medical bill review and cost containment solutions provider, today announced that it has released a new platform that builds upon and enhances the company’s previous adjuster portal to help busy claims professionals orchestrate claim activities.